Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities.
Cullinan Management's zipalertinib met its primary endpoint in a Phase 2b trial for non-small cell lung cancer (NSCLC), demonstrating a promising overall response rate.
Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.